Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4

• DOI: 10.1126/science.1948050
• Publication Date: 2006-10-05T22:10:16Z
• Authors: Paul T. Golumbek; Audrey J. Lazenby; Hyam I. Levitsky; Liz M. Jaffee; Hajime Karasuyama; Mitzi Baker; Drew M. Pardoll
• Keywords: Cancer Immunotherapy

The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses interleukin-4 (IL-4) locally, they rejected predominantly T cell-independent manner. However, animals that IL-4-transfected tumors developed cell-dependent systemic parental tumor. This was tumor-specific and primarily mediated by CD8 + cells. Established could be cured immune response generated injection genetically tumors. These results provide rationale for use lymphokine gene-transfected as modality therapy.